Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Hepatitis C

  Free Subscription


1 Am J Gastroenterol
1 BMC Gastroenterol
1 Eur J Gastroenterol Hepatol
2 Hepatology
4 J Hepatol
1 J Viral Hepat
1 N Engl J Med
1 Nephrol Dial Transplant
1 PLoS Med
3 PLoS One
1 Scand J Gastroenterol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Gastroenterol

  1. RINALDI L, Messina V, Di Marco V, Iovinella V, et al
    Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience.
    Am J Gastroenterol. 2021;116:1248-1255.
    PubMed         Abstract available

    BMC Gastroenterol

  2. ALQAHTANI SA, Broering DC, Alghamdi SA, Bzeizi KI, et al
    Changing trends in liver transplantation indications in Saudi Arabia: from hepatitis C virus infection to nonalcoholic fatty liver disease.
    BMC Gastroenterol. 2021;21:245.
    PubMed         Abstract available

    Eur J Gastroenterol Hepatol

  3. EL KASSAS M, Alboraie M, El-Sayed M, Elbehiry S, et al
    Effect of disease stage and treatment outcomes on the dynamics of liver functions during and after treatment of hepatitis C with directly acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jan 14. doi: 10.1097/MEG.0000000000002043.
    PubMed         Abstract available


  4. NGUYEN LN, Nguyen LNT, Zhao J, Schank M, et al
    Immune activation induces telomeric DNA damage and promotes short-lived effector T cell differentiation in chronic HCV infection.
    Hepatology. 2021 Jun 10. doi: 10.1002/hep.32008.
    PubMed         Abstract available

  5. LIM AG, Stone J, Hajarizadeh B, Byrne M, et al
    Evaluating the prevention benefit of HCV treatment: Modelling the SToP-C treatment as prevention study in prisons.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32002.
    PubMed         Abstract available

    J Hepatol

  6. CLEMENTS O, Eliahoo J, Un Kim J, Taylor-Robinson SD, et al
    Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis.
    J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30543.
    PubMed         Abstract available

  7. HUANG CF, Wei YJ, Wu YT, Chiu YW, et al
    Real world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00351.

  8. KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
    Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
    PubMed         Abstract available

  9. JANJUA NZ, Wong S, Abdia Y, Jeong D, et al
    Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
    J Hepatol. 2021 Jun 4. pii: S0168-8278(21)00401.
    PubMed         Abstract available

    J Viral Hepat

  10. KANG Q, Xu J, Luo H, Tan N, et al
    Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
    J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13558.
    PubMed         Abstract available

    N Engl J Med

  11. PATEL TS, Teterina Mohammed E
    Porphyria Cutanea Tarda Associated with Hepatitis C.
    N Engl J Med. 2021;384:e86.

    Nephrol Dial Transplant

  12. MINUTOLO R, Ravera M, Cupisti A, Nappi F, et al
    Prevalence of hepatitis-C virus infection in non-dialysis CKD patients: a multicenter study in renal clinics.
    Nephrol Dial Transplant. 2021 May 29. pii: 6288494. doi: 10.1093.

    PLoS Med

  13. FADNES LT, Aas CF, Vold JH, Leiva RA, et al
    Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV).
    PLoS Med. 2021;18:e1003653.
    PubMed         Abstract available

    PLoS One

  14. PARK JS, Wong J, Cohen H
    Hepatitis C virus screening of high-risk patients in a community hospital emergency department: Retrospective review of patient characteristics and future implications.
    PLoS One. 2021;16:e0252976.
    PubMed         Abstract available

  15. WYNN A, Tweeten S, McDonald E, Wooten W, et al
    The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018.
    PLoS One. 2021;16:e0251635.
    PubMed         Abstract available

  16. FLEISHER I, Geboy AG, Nichols W, Desale S, et al
    HIV testing in patients who are HCV positive: Compliance with CDC guidelines in a large healthcare system.
    PLoS One. 2021;16:e0252412.
    PubMed         Abstract available

    Scand J Gastroenterol

  17. WALDENSTROM J, Hellstrand K, Westin J, Nilsson S, et al
    Presence of interferon-lambda 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus.
    Scand J Gastroenterol. 2021 Jun 2:1-6. doi: 10.1080/00365521.2021.1922750.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.